Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials

Por Yood, Robert A, Ottery, Faith D, Irish, William, Wolfson, Marsha
Publicado em 2014

Pharmacokinetic and Pharmacodynamic Profiles of Extended Dosing of Epoetin Alfa in Anemic Patients Who Have Chronic Kidney Disease and Are Not on Dialysis

Por McGowan, Tracy, Vaccaro, Nicole M., Beaver, Jessica S., Massarella, Joseph, Wolfson, Marsha
Publicado em 2008

A Randomized Controlled Study of Weekly and Biweekly Dosing of Epoetin Alfa in CKD Patients With Anemia

Por Pergola, Pablo E., Gartenberg, Gary, Fu, Min, Wolfson, Marsha, Rao, Sudhakar, Bowers, Peter
Publicado em 2009

A Randomized Controlled Study Comparing Once-Weekly to Every-2-Week and Every-4-Week Dosing of Epoetin Alfa in CKD Patients with Anemia

Por Pergola, Pablo E., Gartenberg, Gary, Fu, Min, Sun, Steven, Wolfson, Marsha, Bowers, Peter
Publicado em 2010

A Randomized Study of Extended Dosing Regimens for Initiation of Epoetin Alfa Treatment for Anemia of Chronic Kidney Disease

Por Spinowitz, Bruce, Germain, Michael, Benz, Robert, Wolfson, Marsha, McGowan, Tracy, Tang, K. Linda, Kamin, Marc
Publicado em 2008

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout

Por Lipsky, Peter E, Calabrese, Leonard H, Kavanaugh, Arthur, Sundy, John S, Wright, David, Wolfson, Marsha, Becker, Michael A
Publicado em 2014